Sort
4,870 grants matching “glp 1”
Advancing a Lead Candidate Hantavirus Pulmonary Syndrome DNA Vaccine
$660,960Jay Williams Hooper · Geneva Foundation · R01 · FY2012 · AI
Comparative Effectiveness and Safety of Metabolic/Bariatric Surgery, GLP-1, and SGLT-2 Medications for Patients with Obesity and Type 2 Diabetes
$660,172David Eric Arterburn · Kaiser Foundation Research Institute · R01 · FY2025 · DK
Cardiovascular effects of GLP-1 in obesity/metabolic syndrome
$660,047Johnathan D Tune · Indiana University Indianapolis · R01 · FY2017 · HL
Brain systems and behaviors underlying response to obesity treatment in children
$660,035Christian Ludwig Roth · Seattle Children'S Hospital · R01 · FY2022 · DK
Microtubule Regulation of Pancreatic Beta Cell Function and Diabetes
$658,583Irina Kaverina · Vanderbilt University · R01 · FY2022 · DK
Targeted MDM2 degradation for improved treatment for triple-negative breast cancer
$658,561Wei Li · University Of Tennessee Health Sci Ctr · R01 · FY2025 · CA
Countermeasures Against Chemical Threats: Countermeasures Against Cyanide
$658,439Steven E Patterson · University Of Minnesota · U01 · FY2014 · NS
Orally-Bioavailable Peroxynitrite Decomposition Catalyst Targeting Post-Surgical Pain
$658,085Scott L Dax · Cersci Therapeutics, Inc. · R44 · FY2017 · DA
Novel pharmacotherapy strategies for obesity in schizophrenia
$657,518Lars Fredrik Jarskog · Univ Of North Carolina Chapel Hill · R01 · FY2019 · DK
Optimization of Substituted Phenoxyalkyl Pyridinium Oximes as Therapies for Organophosphate Poisoning
$657,302Janice E. Chambers · Mississippi State University · U01 · FY2024 · NS
Clinical and economic value of novel diabetes medications for prevention of cardiovascular disease in type 2 diabetes
$657,295Bart Ferket · Icahn School Of Medicine At Mount Sinai · R01 · FY2021 · HL
Brain systems and behaviors underlying response to obesity treatment in children
$656,880Christian Ludwig Roth · Seattle Children'S Hospital · R01 · FY2023 · DK
Pre-clinical development of gene modified stem cells and CAR T-cells for HIV-1
$656,836Geoffrey Symonds · University Of California Los Angeles · U19 · FY2018 · AI
Effects of Exercise and GLP-1R Agonism on Muscle Microvascular Perfusion and Insulin Action
$656,830Zhenqi Liu · University Of Virginia · R01 · FY2023 · DK
Effects of Exercise and GLP-1R Agonism on Muscle Microvascular Perfusion and Insulin Action
$656,830Zhenqi Liu · University Of Virginia · R01 · FY2021 · DK
Effects of Exercise and GLP-1R Agonism on Muscle Microvascular Perfusion and Insulin Action
$656,830Zhenqi Liu · University Of Virginia · R01 · FY2022 · DK
Effects of Exercise and GLP-1R Agonism on Muscle Microvascular Perfusion and Insulin Action
$656,830Zhenqi Liu · University Of Virginia · R01 · FY2020 · DK
Effects of Exercise and GLP-1R Agonism on Muscle Microvascular Perfusion and Insulin Action
$656,830Zhenqi Liu · University Of Virginia · R01 · FY2025 · DK
Enhancing Weight Loss Maintenance with GLP-1 in Adolescents with Severe Obesity
$656,680Aaron S Kelly · University Of Minnesota · R01 · FY2019 · DK
Targeted Nano-enhanced Optical Delivery of opsin for dry-AMD therapy
$656,220Samarendra Kumar Mohanty · Nanoscope Technologies, Llc · R44 · FY2022 · EY
Pathophysiological mechanisms in the brain's endogenous glucagon-like peptide 1 system mediated by obesogenic diets
$655,971James Andrew Hardaway · University Of Alabama At Birmingham · R01 · FY2024 · DK
Imaging tumor-associated macrophages in head and neck squamous cell carcinoma using fluorine-19 MRI
$655,700Eric T Ahrens · University Of California, San Diego · R01 · FY2024 · CA
Imaging tumor-associated macrophages in head and neck squamous cell carcinoma using fluorine-19 MRI
$655,698Eric T Ahrens · University Of California, San Diego · R01 · FY2025 · CA
Development of Non-Catalytic Peptide Inhibitors of Focal Adhesion Kinase (FAK) for Use in Melanoma
$654,706Timothy A Marlowe · Faknostics, Llc · R42 · FY2023 · CA
A Novel Topical HSP90 Inhibitor (CTXT-102) in the Treatment of Mild to Moderate Plaque Psoriasis
$654,034Christina Grek · Regranion, Llc · R44 · FY2017 · AR